This study will assess the safety and efficacy of generic TDF from Governmental Pharmaceutical Organization (GPO) in HIV-infected children
Name: tenofovir (TDF)
Type: Drugtenofovir (TDF)
Description: Number of patients who have viral load less than 50 copies/ml at week 48 and week 96
Measure: viral load Time: week 48 and 96Description: Number of patients with renal toxicity assessed by GFR and with proximal tubular effect
Measure: renal status Time: weeks 24, 48, 72, and 96Description: Agreement between self reported adherence by visual analogue scale (VAS) pill count and TDM Sensitivity and specificity of self-reported adherence and pill count against gold standards of TDM and undetectable viral load
Measure: adherence Time: every 3 monthsDescription: Resistant mutations in patients who fail TDF-based regimen and response to new regimen
Measure: resistance Time: every 3 monthsDescription: Proportion of patients who develop adverse events which are related to TDF and other ARVs
Measure: adverse events Time: weeks 24, 48, 72, and 96Cohort
There is one SNP
Inclusion Criteria: - children who are changing to TDF due to adherence problem or treatment failure - children who are already on TDF due to their clinical indication Exclusion Criteria: - child/caretaker refuse to participate in this study - cannot adhere to the study schedule Inclusion Criteria: - children who are changing to TDF due to adherence problem or treatment failure - children who are already on TDF due to their clinical indication Exclusion Criteria: - child/caretaker refuse to participate in this study - cannot adhere to the study schedule HIV-infected Thai Children TDF is a nucleotide reverse transcriptase inhibitor (NRTI) which can be taken only once per day and continues to have good efficacy even in patients who have resistance to other NNRTI in the absence of K65R mutation. --- K65R ---